Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent

European Journal of Pharmacology

Volumn 304, Issue 1-3, 1996, Pages 129-134

  Murakami, Nobuya ^a   Ohta, Masahiko ^a   Hashimoto, Koji ^a   Kato, Katsuaki ^a   Mizota, Masahiro ^a   Miwa, Ichitomo ^b   Okuda, Jun ^b   Inoue, Gen ^c   Kuzuya, Hideshi ^c   Nakao, Kazuwa ^c   Imura, Hiroo ^c  

^a MOCHIDA PHARMACEUTICAL CO   (Japan)

^b MEIJO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

antihyperglycemic effect; genetically obese rodent; hyperinsulinemic euglycemic clamp; insulin resistance; M16209

Indexed keywords

1 [(3 BROMO 2 BENZO[B]FURANYL)SULFONYL]HYDANTOIN; ANTIDIABETIC AGENT; CHOLESTEROL; FATTY ACID; GLUCOSE; INSULIN; LIPID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; GENETIC DISORDER; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIVER; METABOLIC CLEARANCE RATE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; RODENT;

EID: 0030598615     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00121-5     Document Type: Article

References (14)

1. Kato, K., K. Nakayama, M. Ohta, N. Murakami, K. Murakami, M. Mizota, I. Miwa and J. Okuda, 1990, Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats, Jpn. J. Pharmacol. 54, 355.
2. Kato, K., K. Nakayama, M. Mizota, I. Miwa and J. Okuda, 1991a, Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil, Chem. Pharm. Bull. 39, 1540.
3. Kato, K., K. Nakayama, M. Ohta, N. Murakami, K. Murakami, M. Mizota, I. Miwa and J. Okuda, 1991b, Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats, Eur. J. Pharmacol. 193, 185.
4. Kergort, M. and B. Portha, 1985, In vivo hepatic and peripheral insulin sensitivity in rats with non-insulin-dependent diabetes induced by streptozotocin, Diabetes 34, 1120.
5. Modan, M., H. Halkin and A. Lusky, 1988, Hyperinsulinemia is characterized by jointly disturbed plasma VLDL, LDL and HDL levels. A population-based study, Arteriosclerosis 8, 227.
6. Nakayama, K., N. Murakami, M. Ohta, K. Kato, K. Ida, M. Mizota, I. Miwa and J. Okuda, 1995a, Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats, Eur. J. Pharmacol. 276, 77.
7. Nakayama, K., N. Murakami, M. Ohta, K. Kato, T. Notsu, M. Mizota, I. Miwa and J. Okuda, 1995b, Effect of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats, Eur. J. Pharmacol. 276, 85.
8. Pelkonen, R., T.A. Miettinen and M.R. Taskinen, 1968, Effect of acute elevation of plasma glycerol, triglyceride and FFA levels on glucose utilization and plasma insulin, Diabetes 17, 76.
9. Radziuk, J. and H.L.A. Lickley, 1985, The metabolic clearance of glucose: measurement and meaning. Diabetologia 28, 315.
10. Reaven, G. M. and M.S. Greenfield, 1981, Diabetic hypertriglyceridemia. Evidence for three clinical syndromes. Diabetes (Suppl. 2) 30, 66.
11. Shafrir, E., 1992, Animal models of non-insulin-dependent diabetes, Diabetes/Metabolism Rev. 8, 179.
12. Steele, R., 1959, Influence of glucose loading and of injected insulin on hepatic glucose output, Ann. NY Acad. Sci. 82, 420.
13. Terrettaz, J. and B. Jeanrenaud, 1983, In vivo hepatic and peripheral insulin resistance in genetically obese fa/fa rats, Endcrinology 112, 1346.
14. Thiebaud, D., R.A. Defronzo, E. Jacot, A. Golay, K. Acheson, E. Maeder, E. Jequier and J.P. Felber, 1982, Effect of long chain triglyceride infusion on glucose metabolism in man, Metabolism 31, 1128.